S'abonner

Maternal Instruction About Jaundice and the Incidence of Acute Bilirubin Encephalopathy in Nigeria - 20/05/20

Doi : 10.1016/j.jpeds.2020.01.050 
Richard P. Wennberg, MD 1, , Stephen Oguche, FMCP 2, , Zainab Imam, FWACP 3, Zubaida L. Farouk, FWACP 4, Isa Abdulkadir, FMCPaed 5, Paul D. Sampson, PhD 6, Tina M. Slusher, MD 7, Fidelia Bode-Thomas, FWACP 2, Bose O. Toma, FWACP 2, Christopher S. Yilgwan, FWACP 2, David Shwe, FMCPaed 2, Akinyemi O. Ofakunrin, FMCPaed 2, Udochukwu M. Diala, FMCPaed 2, Chris Isichei, BMBCh 2, Victor Pam, FMCOG 2, Zuwaira Hassan, MBBS 2, Shehu U. Abdullahi, FWACP 4, Fatima Usman, FWACP 4, Binta W. Jibir, MSc 4, Idris Y. Mohammed, MSc 4, Hadiza A. Usman, MBBS 4, Muhammed Abdusalam, MBBS 4, Aisha Kuliya-Gwarzo, MSc 4, Fatima I. Tsiga-Ahmad, MBBS 4, Laila Umar, MPH 4, William N. Ogala, FWACP 5, Fatimatu Abdullahi, FWACP 5, Laila Hassan, FWACP 5, Saratu Purdue, MBBS 5, Troy Lund, MD 7, Carlos D. Coda-Zabetta, PhD 8
1 Department of Pediatrics, University of Washington, Seattle, WA 
2 Department of Pediatrics, University of Jos, Jos, Nigeria 
3 Massey Street Children's Hospital, Lagos, Nigeria 
4 Department of Pediatrics, Bayero University, Kano, Nigeria 
5 Department of Pediatrics, Ahmadu Bello University, Zaria, Nigeria 
6 Department of Statistics, University of Washington, Seattle, WA 
7 Department of Pediatrics, University of Minnesota, Minneapolis, MN 
8 Bilimetrix, s.r.l., Trieste, Italy 

Abstract

Objective

To evaluate whether teaching mothers about neonatal jaundice will decrease the incidence of acute bilirubin encephalopathy among infants admitted for jaundice.

Study design

This was a multicenter, before–after and cross-sectional study. Baseline incidences of encephalopathy were obtained at 4 collaborating medical centers between January 2014 and May 2015 (Phase 1). Structured jaundice instruction was then offered (May to November 2015; Phase 2) in antenatal clinics and postpartum. Descriptive statistics and logistic regression models compared 3 groups: 843 Phase 1 controls, 338 Phase 2 infants whose mothers received both antenatal and postnatal instruction (group A), and 215 Phase 2 infants whose mothers received no instruction (group B) either because the program was not offered to them or by choice.

Results

Acute bilirubin encephalopathy occurred in 147 of 843 (17%) Phase 1 and 85 of 659 (13%) Phase 2 admissions, which included 63 of 215 (29%) group B and 5 of 338 (1.5%) group A infants. OR for having acute bilirubin encephalopathy, comparing group A and group B infants adjusted for confounding risk factors, was 0.12 (95% CI 0.03-0.60). Delayed care-seeking (defined as an admission total bilirubin ≥18 mg/dL at age ≥48 hours) was the strongest single predictor of acute bilirubin encephalopathy (OR 11.4; 6.6-19.5). Instruction decreased delay from 49% to 17%. Other major risk factors were home births (OR 2.67; 1.69-4.22) and hemolytic disease (hematocrit ≤35% plus bilirubin ≥20 mg/dL) (OR 3.03; 1.77-5.18). The greater rate of acute bilirubin encephalopathy with home vs hospital birth disappeared if mothers received jaundice instruction.

Conclusions

Providing information about jaundice to mothers was associated with a reduction in the incidence of bilirubin encephalopathy per hospital admission.

Le texte complet de cet article est disponible en PDF.

Keywords : kernicterus, low-middle income country, risk factors, maternal instruction, neonatal jaundice, hyperbilirubinemia, acute bilirubin encephalopathy

Abbreviations : BIND, G6PD, P1, TSB


Plan


 Supported in part by Saving Lives at Birth partners: the United States Agency for International Development, the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UK Government (FOG award no. AID-OAA-F-13-00072 to Bilimetrix s.r.l.). The study was conceived while performing validation studies for a point of care bilirubin assay (Bilistick) supported by Bilimetrix s.r.l. Bilimetrix provided support for bilirubin assays, teaching materials, and data collation and storage. The design, execution, analysis, and manuscript preparation are solely the product of the Stop Kernicterus in Nigeria coalition and may or may not reflect the opinion of the sponsors.


© 2020  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 221

P. 47 - juin 2020 Retour au numéro
Article précédent Article précédent
  • Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants
  • Sagori Mukhopadhyay, Karen M. Puopolo, Nellie I. Hansen, Scott A. Lorch, Sara B. DeMauro, Rachel G. Greenberg, C. Michael Cotten, Pablo J. Sánchez, Edward F. Bell, Eric C. Eichenwald, Barbara J. Stoll, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
| Article suivant Article suivant
  • Long-term Healthcare Utilization by Medicaid Enrolled Children with Neonatal Abstinence Syndrome
  • Walter M. Taylor, Yewei Lu, Shuang Wang, Lena S. Sun, Guohua Li, Caleb Ing

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.